CRISPR Therapeutics Company Profile

12:46 EDT 19th March 2019 | BioPortfolio

CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human genetic diseases. Its vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. CRISPR Therapeutics is a Swiss company with operations in London, UK.

News Articles [1879 Associated News Articles listed on BioPortfolio]

CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies

ZUG, Switzerland and CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. 09, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP) and MaxCyte today announced the expansion of their existing relati...

Beam Brings In $135M to Turn CRISPR Base Editing into Drugs

Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that swap...

Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte’s cell engineering platform. The partnership is an...Read More... The post Deals this...

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/D...

CRISPR, MaxCyte expand partnership into immuno-oncology

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based ther...

CRISPR Therapeutics and ViaCyte Collaborate to Tackle Type 1 Diabetes

CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?

CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored...   

Vertex, CRISPR Therapeutics become first U.S. companies to enter clinic with CRISPR therapy

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [797 Associated PubMed Articles listed on BioPortfolio]

CRISPR-Cas: a tool for cancer research and therapeutics.

In the past decade, the development of a genome-editing technology mediated by CRISPR has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems have enabled important ad...

Challenges and advances of CRISPR-Cas9 genome editing in therapeutics.

Delivery Approaches for CRISPR/Cas9 Therapeutics In Vivo: Advances and Challenges.

Therapeutic gene editing is becoming a viable biomedical tool with the emergence of the CRISPR/Cas9 system. CRISPR-based technologies have promise as a therapeutic platform for many human genetic dise...

CRISPR-Cas in Streptococcus pyogenes.

The discovery and characterization of the prokaryotic CRISPR-Cas immune system has led to a revolution in genome editing and engineering technologies. Despite the fact that most applications emerged a...

CRISPR/Cas9-mediated genome editing induces gene knockdown by altering the pre-mRNA splicing in mice.

Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated protein 9 (CRISPR/Cas9) has been wildly used to generate gene knockout models through inducing indels causing frame-shift. H...

Clinical Trials [190 Associated Clinical Trials listed on BioPortfolio]

A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

This is an open-label and triple cohort study of the safety and efficacy of TALEN and CRISPR/Cas9 to possibly treat HPV Persistency and human cervical intraepithelial neoplasiaⅠwithout i...

Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances

The investigators performed this study to evaluate the safety and feasibility of transplantation with CRISPR/Cas9 CCR5 gene modified CD34+ hematopoietic stem/progenitor cells for patients ...

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric anti...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

Companies [1319 Associated Companies listed on BioPortfolio]

CRISPR Therapeutics

CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human geneti...

Intellia Therapeutics

Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technolo...

Intellia Therapeutics, Inc.

Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Intellia inten...

KSQ Therapeutics

KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high confidence drug development. The company is advancing a pipeline o...

Hunterian Medicine LLC

Headquartered in Cambridge, Massachusetts, Hunterian Medicine LLC is a leading gene-editing company working to cure genetic diseases by correcting DNA mutations using its innovati...

More Information about "CRISPR Therapeutics" on BioPortfolio

We have published hundreds of CRISPR Therapeutics news stories on BioPortfolio along with dozens of CRISPR Therapeutics Clinical Trials and PubMed Articles about CRISPR Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CRISPR Therapeutics Companies in our database. You can also find out about relevant CRISPR Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record